louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05814120: Effectiveness of Basic Life Support Training for Rural Community Dwelling Elderly
Official title: Chang Gung University of Science and Technology
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Community Dwelling
Keywords: Basic Life Support
Rural Community Dwelling
Elderly
Lead sponsor: Chang Gung University of Science and Technology
Sponsor class: OTHER
First posted: 2023-04-14
Enrollment: 218
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this pre-post study is to test the effectiveness of basic life support (BLS) training for rural community-dwelling Elderly. The main question it aims to answer are can the training program tailored for rural elderly improve basic life support knowledge, attitude, and skills? Participants will receive an innovative BLS training program.


Eligibility criteria: Inclusion Criteria:

age older than 65-year-old, intact cognition, coordinated activities, and no history of severe cardiovascular disease, asthma, or lower extremity impairment.

Exclusion Criteria:

severe visual and hearing impairment, impractical to move, and mental illness.

Primary outcomes:
measure: Changes to the BLS Knowledge Questionnaire
timeFrame: Completion by study, average 60 minutes.
measure: Changes to the BLS attitude Questionnaire
timeFrame: Completion by study, average 60 minutes.
measure: The observable BLS skill checklist
timeFrame: Completion by study, average 60 minutes.
Secondary outcomes:
Other outcomes:
Locations:
city: Chiayi City
country: Taiwan
facility: Chang Gung University of Science and Technology
Study officials:
References:
Clinical trial NCT03605420: Relatives Visit Prior to Hospital Admission & Intensive Care Unit
Official title: Effects of the Visit Prior to Hospital Admission on Anxiety, Depression and Satisfaction of Family in an Intensive Care Unit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Depression
Care Unit Syndrome
Lead sponsor: Universidad de León
Sponsor class: OTHER
First posted: 2018-07-30
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The present study evaluates the effects of the visit prior to hospital admission on anxiety, depression and satisfaction of family in an intensive care unit.


Eligibility criteria: Inclusion Criteria:

* Family of a patient for hospital admission for surgery

Exclusion Criteria:

* Cognitive impairment

Primary outcomes:
measure: The Hospital Anxiety and Depression Scale
timeFrame: Change from Baseline anxiety and depression at 90 days
Secondary outcomes:
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Hospital La Princesa
Study officials:
References:
Clinical trial NCT01461720: Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct
Official title: An Open Lable, Phase II Exploratory Study Assessing the Efficacy of Intravenous Autologous Mesenchymal Stem Cells in Patients With Middle Cerebral Artery Infarct
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Middle Cerebral Artery Infarction
Keywords: Bone marrow
Autologous
Mesenchymal stem cells
Unilateral middle cerebral artery infarct
Lead sponsor: National University of Malaysia
Sponsor class: OTHER
Collaborators: name: Cytopeutics Sdn. Bhd.
First posted: 2011-10-28
Enrollment: 50
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to determine the efficacy of intravenous transplantation of autologous bone marrow-derived mesenchymal stem cells in patients with acute middle cerebral artery infarct.


Eligibility criteria: Inclusion Criteria:

* Experiences stroke onset within 2 weeks to 2 months
* NIHSS score of \>10-35
* Never received or failed thrombolysis
* Evidence of unilateral middle cerebral artery infarct on brain MRI

Exclusion Criteria:

* Medically unfit (eg. those are unstable haemodynamically despite treatment, with worsening conscious level and with other serious medical co-morbidity)
* Evidence of any tumor or other space-occupying lesion on brain MRI
* Evidence of hemorrhagic stroke on brain CT or MRI
* Experiences transient ischemic attack or lacunar infarct
* Has any acute or chronic infections such as Hepatitis B, Hepatitis C and HIV
* Is diagnosed with concurrent malignancy or primary hematological disorders
* Renal impairment indicated with serum creatinine greater than 200 umol/l or creatinine clearance less than 30 ml/min
* Liver impairment indicated with serum aspartate transaminase and serum alanine transaminase greater than 4 times upper limit of the normal range
* Any contraindication to stem cell transplantation or bone marrow biopsy
* Any co-morbidity which will compromise the ability to obtain adequate stem cells (eg. chronic debilitating diseases, frail patients and patients with known osteoporosis)
* Any contraindication to brain MRI (eg. metal implants, pacemaker, joint implants and ocular implants)

Primary outcomes:
measure: Change in NIH Stroke Scale
timeFrame: 1 year
measure: Change in Barthel Index
timeFrame: 1 year
measure: Change in modified Rankin Scale
timeFrame: 1 year
measure: Change in size of infarct based on brain MRI stroke sequences
timeFrame: 1 year
Secondary outcomes:
measure: Change in Stroke Specific Quality of Life Scale
timeFrame: 1 year
measure: Change in Stroke Impact Scale
timeFrame: 1 year
Other outcomes:
Locations:
city: Kuala Lumpur
country: Malaysia
facility: UKM Medical Centre
Study officials:
affiliation: UKM Medical Centre
name: Norlinah Mohamed Ibrahim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04389320: Antimalarial and Covid 19 in Rheumatoid Arthritis
Official title: Antimalarial and Covid 19 in Rheumatoid Arthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-05-15
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: rheumatoid arthritis patients

Brief summary: The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents.

Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

Detailed description: The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus.(1) . These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents.

Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

It is difficult to carefully evaluate the onslaught of information that has emerged regarding potential COVID-19 therapies within a few months' time in early 2020. A brief but detailed approach regarding how to evaluate resulting evidence of a study has been presented by F. Perry Wilson, MD, MSCE. By using the example of a case series of patients given hydroxychloroquine plus azithromycin, he provides clinicians with a quick review of critical analyses.

Eligibility criteria: Inclusion Criteria:

* rheumatoid arthritis recieving hydroxychloroquine chest infection

Exclusion Criteria:

* patients not used hydroxychloroquine

Primary outcomes:
measure: immunoglobulin mesurement
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Manal Hassanien
state: Yes
Study officials:
References:
Clinical trial NCT03016520: Pharmacokinetics and Safety Study of DWJ1392 and DWC20164 in Healthy Male Volunteers
Official title: An Open-label, Randomized, Single-dose, 2-way Crossover Study to Compare the Pharmacokinetics and Safety of DWJ1392 and DWC20164 in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2017-01-10
Enrollment: 28
Sex: MALE
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study to Compare the safety and pharmacokinetics of DWJ1392 and DWC20164 in healthy male volunteers.


Eligibility criteria: Inclusion Criteria:

* No clinically significant findings
* Age 19-50 years at screening

Exclusion Criteria:

* Who has allergy to investigational product

Primary outcomes:
measure: Maximum Plasma Concentration (Cmax)
timeFrame: 0-72 hours
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: 0-72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul ST. Mary's Hospital
Study officials:
References:
Clinical trial NCT05191420: Conversations You Want About Corona Virus Disease (COVID-19)
Official title: BECAUSE YOU MATTER: Conversations You Want About COVID-19
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Covid19
Keywords: Vaccines
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2022-01-13
Enrollment: 23000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Diverse health care professions and community members

Brief summary: Web-enabled virtual topical guide: develop virtual conversations for each concern and intensity level

Detailed description: Study will pilot test the virtual topical discussion guide with diverse health care professions and community members to confirm it is clear, relevant, understandable, and culturally appropriate

Eligibility criteria: Inclusion Criteria:

* greater than or equal to 18 years of age
* English or Spanish speaking only

Exclusion Criteria:

* less than 18 years of age
* not English or Spanish speaking

Primary outcomes:
measure: Time spent with the guide
timeFrame: Week 4
measure: Number of clinics viewed in the guide
timeFrame: Week 4
measure: Number of content areas accessed
timeFrame: Week 4
measure: Time spent with each content area
timeFrame: Week 4
measure: Helpfulness of Tool
timeFrame: Week 4
measure: Number of Subjects saving responses
timeFrame: Week 4
Secondary outcomes:
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest Health Sciences
state: North Carolina
Study officials:
affiliation: Wake Forest Health Sciences
name: Katherine A Poehling, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02417220: Weight Watchers Online 2015
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Overweight
Body Weight
Lead sponsor: The Miriam Hospital
Sponsor class: OTHER
Collaborators: name: WW International Inc
name: University of Tennessee
First posted: 2015-04-15
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to conduct a randomized controlled trial to compare the weight losses produced by the Weight Watchers Online program revised for 2015 (WWO2015) and WWO2015 plus the provision of an electronic scale and weekly email feedback on weight loss (WWO2015 Enhanced), over a 6-month period.


Eligibility criteria: Inclusion Criteria:

* Age 18-70 years
* Body mass index (BMI) between 27 and 40 kg/m2
* Both genders will be recruited; At least 10% of participants will be men. Enrollment of women will be capped at n = 324 (90%) to meet this goal.
* All ethnic groups will be recruited, with a goal of recruiting 10% minorities
* English speaking
* Have access to the Internet via a computer, and basic computer skills

Exclusion Criteria:

* Report health problems that make weight loss or unsupervised exercise unsafe or unreasonable
* Report a heart condition, chest pain during periods of activity or rest, or loss of consciousness on the Physical Activity Readiness Questionnaire1
* Are currently pregnant or breastfeeding, or intend to become pregnant in the next 12 months
* Are planning to move outside of the state within the next 12 months
* Report any cognitive or physical limitations that preclude use of a personal computer
* Have participated in a study conducted by the WCDRC or UT in the past 2 years
* Have followed a commercial weight-loss program within the previous 6 months or who are currently following a commercial weight loss program
* Weight loss of ≥ 5% of initial body weight in the last 6 months
* History of clinically diagnosed eating disorder excluding Binge Eating Disorder.
* Previous surgical procedure for weight loss
* Currently taking weight loss medication
* Treatment of cancer within the last 6 months

Primary outcomes:
measure: Change in body weight, measured in kilograms
timeFrame: 3 and 6 months after randomization
Secondary outcomes:
measure: Engagement with the electronic intervention system, measured by number of body weights, foods, and physical activity bouts recorded per week
timeFrame: 3 and 6 months after randomization
Other outcomes:
Locations:
city: Providence
country: United States
facility: Weight Control and Diabetes Resarch Center
state: Rhode Island
city: Knoxville
country: United States
facility: University of Tennessee
state: Tennessee
Study officials:
References:
Clinical trial NCT04228120: Effects of a Self-regulation Program on Self-care Behaviour of Heart Failure Patients
Official title: The Effects of a Self-regulation Program on Self-care Behaviour in Patients With Heart Failure: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Keywords: Self-care behaviour
Self-regulation
Heart Failure
Lead sponsor: National Yang Ming Chiao Tung University
Sponsor class: OTHER
First posted: 2020-01-14
Enrollment: 82
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This RCT study aims to examine the effects of a self-regulation programme on the self-care behaviour and quality of life of patients with heart failure. The following hypothesis was tested: Heart failure patients who receive the self-regulation program will report significant improvements in self-care behaviours after four weeks of the self-regulation programme. In contrast, patients in the control group showed no significant differences.

Detailed description: Eight two patients with heart failure were randomly assigned into the intervention (n = 41) or control group (n = 41). The intervention group participated in a 4-week self-regulation programme, including 20 to 30 minutes of individual self-regulation education and 15 to 20 minutes of telephone follow-up twice per week for four weeks. The control group received only routine outpatient care. Self-care behaviour was measured by the Self-Care of Heart Failure Index at baseline, 4 weeks and 8 weeks after patients were enrolled. Quality of life was measure with the Minnesota Living with Heart Failure questionnaire

Eligibility criteria: Inclusion Criteria:

* aged 20 years or older with heart failure diagnosed by a cardiologist (ICD-9:428)
* willing to communicate and participate in this study
* had clear consciousness

Exclusion Criteria:

* a diagnosis of cancer
* a diagnosis of mental illness including anxiety and depression
* had cognitive impairment
* a diagnosis of lung disease, such as asthma or chronic obstructive pulmonary disease
* a diagnosis of renal failure

Primary outcomes:
measure: Changes in three self-care behaviour subscale scores
timeFrame: 4 weeks and 8 weeks
Secondary outcomes:
measure: Change in quality of life scores
timeFrame: 4 weeks and 8 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Professor
name: Ai-Fu Chiou, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05620420: A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma
Official title: A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psychological Distress
Insomnia
Somatic Symptoms
Keywords: multiple myeloma
mental health
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2022-11-17
Enrollment: 501
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients will be recruited form 14 medical centers.

Brief summary: Multiple myeloma patients with normal ability of communication and understanding will be enrolled. DT, GAD-7, PHQ-15 and PSQI scales are designed to assess the mental health status of the patients. Demographic and disease data of patients will be collected as well. The main aim is to explore the factors affecting the mental health of myeloma patients.


Eligibility criteria: Inclusion Criteria:

1. Patients with symptomatic multiple myeloma were diagnosed according to the criteria of Chinese multiple myeloma diagnosis and treatment guidelines (revised in 2022).
2. Age ≥18 years, with junior high school education or above. Patients have normal ability of communication and understanding.
3. Informed consent has been signed.

Exclusion Criteria:

1. Who has kinship with other enrolled patients.
2. Life expectancy of\< 6 months.

Primary outcomes:
measure: morbidity of psychological distress in patients with multiple myeloma.
timeFrame: Baseline (the time when the patient is enrolled to the study)
Secondary outcomes:
measure: morbidity of anxiety in patients with multiple myeloma.
timeFrame: Baseline (the time when the patient is enrolled to the study)
measure: morbidity of insomnia in patients with multiple myeloma.
timeFrame: Baseline (the time when the patient is enrolled to the study)
Other outcomes:
Locations:
city: Shanghai
country: China
facility: shanghai Jiaotong University School of Medicine, Renji Hospital
state: Shanghai
Study officials:
affiliation: RenJi Hospital
name: Jian Hou
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05088720: Misoprostol for Management of Women With an Incomplete Miscarriage
Official title: Comparative Study Between Two Doses of Misoprostol in Women With Incomplete First-trimester Miscarriage After Misoprostol Treatment: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Miscarriage
Lead sponsor: Aswan University Hospital
Sponsor class: OTHER
First posted: 2021-10-22
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: a double-blind placebo-controlled randomized trial
Primary purpose: TREATMENT

Brief summary: Miscarriage is defined as the spontaneous loss of a pregnancy before 24 weeks gestation, that is, before fetal viability. The clinical signs of miscarriage are usually vaginal bleeding associated with abdominal pain and cramping. The miscarriage is named 'complete' or 'incomplete' according to whether or not tissues are retained in the uterus. If a woman has minimal bleeding but her cervix is closed, this is known as a 'threatened miscarriage. However; if the pregnancy is still inside the uterus but the cervix is open, this is described as an 'inevitable miscarriage', which it will not usually be possible to save the fetus.

Detailed description: the aim of the study is to evaluate 2 doses with misoprostol in Women With Incomplete First-trimester Miscarriage After Misoprostol Treatment

Eligibility criteria: Inclusion Criteria:

* Women with confirmed incomplete induced miscarriage, less than 12 weeks' gestation.
* No known allergy to misoprostol.
* Women who will be hemodynamically stable.
* Good access to emergency facilities

Exclusion Criteria:

* Women with signs of severe infection ( fever \> 38°)
* Women with severe vaginal bleeding
* Women are known to have allergies to prostaglandins
* Severe abdominal pain requiring immediate intervention

Primary outcomes:
measure: The number of patients with complete miscarriage at 1 week
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University Hospital
Study officials:
References: